Back to top
more

Acceleron Pharma Inc. (XLRN)

(Delayed Data from NSDQ)

$41.49 USD

41.49
271,799

+1.00 (2.47%)

Updated May 3, 2019 04:00 PM ET

After-Market: $41.50 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates

Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Acceleron Pharma (XLRN)

Acceleron Pharma (XLRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View

Merck (MRK) beats Q3 estimates for earnings and sales. It raises financial guidance for 2021. The stock moves up in the pre-market trading session.

Merck (MRK) to Report Q3 Earnings: What's in the Cards?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.

Core PCE Inflation Stays at Record-High in August

Core PCE Inflation Stays at Record-High in August.

Mark Vickery headshot

Merck (MRK) Develops Pill to Lessen Covid Symptoms

Results of a trial developed with Cambridge, MA-based Ridgeback Biotherapeutics are positive for an oral antiviral treatment for Covid-19.

Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio

Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate.

Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More

Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.

Acceleron (XLRN) Stock Up on Takeover Rumors for $11 Billion

Acceleron (XLRN) up on rumors of a potential acquisition by a pharma giant for $11 billion or $180 per share.

Acceleron (XLRN) Q2 Loss Wider Than Expected, Revenues Miss

Acceleron (XLRN) reports a wider loss in the second quarter of 2021 on higher costs and lower revenues.

Acceleron Pharma (XLRN) Reports Q2 Loss, Misses Revenue Estimates

Acceleron (XLRN) delivered earnings and revenue surprises of -14.13% and -10.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Acceleron Pharma (XLRN) to Report a Decline in Earnings: What to Look Out for

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates

Acceleron (XLRN) delivered earnings and revenue surprises of 7.23% and -9.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Acceleron Pharma (XLRN) Report Negative Earnings Next Week? What You Should Know

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Acceleron (XLRN) Up 0.5% Since Last Earnings Report?

Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Acceleron (XLRN) Stock Jumps 3.3%: Will It Continue to Soar?

Acceleron (XLRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat

Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

During Novavax's (NVAX) upcoming fourth-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

What's in the Cards for BioNTech (BNTX) This Earnings Season?

On BioNTech's (BNTX) fourth-quarter earnings call, investors are likely to focus on sales number for its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.

Inovio (INO) to Report Q4 Earnings: What's in the Cards?

On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.

    Analysts Estimate Acceleron Pharma (XLRN) to Report a Decline in Earnings: What to Look Out for

    Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals

    The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals

    Ekta Bagri headshot

    5 Biotech Stocks That More Than Doubled This Year

    The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

    5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic

    We take a sneak peek into five healthcare stocks that have performed well in 2020 driven by their improved capabilities to cope with the COVID-19 crisis.